Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COLUMN
COLUMN
-
It’s the Everyday Leaders Your Organization Needs
December 11, 2020
-
Let’s Be Grateful for the Chaos of the Year That Was
November 18, 2020
-
Empower Smarter Decision Making with Big Data
October 23, 2020
-
5 Improvements when Recruiting Female Employees
September 25, 2020
-
Think Differently for Post-Pandemic Success
August 14, 2020
-
The Crisis That Ignited a Workplace Revolution
July 6, 2020
-
Smart Strategies for Building Your Dream Team
March 17, 2020
-
A Peek into the Digital Pharmaceutical Industry
November 21, 2019
-
Plant the Seeds of Success when Battling a Crisis
September 30, 2019
-
Practice Makes Perfect - Even in Marketing!
August 19, 2019
-
Failing Isn’t the Issue. What You Do Next Is All that Counts
July 26, 2019
-
Big Question Mark to Pricey Drug Bashing
July 12, 2019
-
The Science Behind Stage Fright, and How You Can Overcome It
June 28, 2019
-
The Power in Teaching Your Team “How to Speak”
May 28, 2019
-
Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
-
No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
-
6 Core Elements of Recruitment Mastery
March 22, 2019
-
Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
-
Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
-
Expat Truths from the Japanese Medical Device World
December 3, 2018
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…